FDA approves Lipella's oral treatment access program
PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...
New Atlas8d
FDA approves new class of painkiller – the first in more than 20 years
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.
Hosted on MSN7mon
FDA approves another Alzheimer’s drug that can modestly slow disease
The FDA approved ... declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion. The main safety issue was brain swelling and bleeding ...
Nasdaq1mon
FDA Set To Decide On Ionis' Olezarsen For Rare Inherited Lipid Disorder
Despite the critical need for treatment, there are currently no FDA ... severe swelling episodes. The FDA decision on Donidalorsen is expected on August 21, 2025. This potential approval would ...